fda removes semaglutide from shortage list FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know fda remove semaglutide from shortage

Retatrutide, a triple GLP-1/GIP/glucagon agonist, represents the future of weight loss, demonstrating mean weight loss approaching or exceeding 20% in phase 2 trials

This central mechanism is what distinguishes it from GLP-1 medications, which work through the incretin system

Realistic expectations are essentialthis is not a magic bullet for rapid dramatic weight loss

Doctors weigh in

Your Path to Affordable and Effective Weight Loss Monthly telehealth visits, prescription medication, and 24/7 messaging with your doctor

Additionally, we cover effective communication strategies for mediating situations involving high-conflict individuals, emphasizing empathy and problem-solving approaches